Free tool
FAERS Monitor: Vistogard
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208159 or its brand name (Vistogard, Uridine Triacetate). Reports on generic versions are filed under their own applications.
Reports
125
Serious
66
53% of reports
Hospitalization
31
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- complication associated with device22
- vomiting22
- diarrhoea20
- death13
- thrombocytopenia13
- mucosal inflammation12
- nausea12
- inappropriate schedule of product administration10
- off label use10
- neutropenia9
- hypokalaemia8
- asthenia7
- product dose omission issue7
- dysphagia6
- decreased appetite5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 15 |
| 2017 | 18 |
| 2018 | 15 |
| 2019 | 13 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 13 |
| 2025 | 12 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| complication associated with deviceSignal | 22 | 255.3 | 174.7 | 5,317 |
| mucosal inflammationSignal | 12 | 77.2 | 45.1 | 828 |
| hypokalaemiaSignal | 8 | 29.2 | 14.9 | 191 |
| thrombocytopeniaSignal | 13 | 19.6 | 11.7 | 212 |
| neutropeniaSignal | 9 | 11.1 | 5.9 | 74 |
| dysphagiaSignal | 6 | 10.6 | 4.9 | 43 |
| inappropriate schedule of product administrationSignal | 10 | 9.3 | 5.2 | 67 |
| vomitingSignal | 22 | 7.9 | 5.4 | 128 |
| diarrhoeaSignal | 20 | 5.2 | 3.5 | 66 |
| product dose omission issueSignal | 7 | 4.0 | 2.0 | 13 |
| decreased appetiteSignal | 5 | 3.6 | 1.5 | 7 |
| astheniaSignal | 7 | 3.1 | 1.5 | 8 |
| nauseaSignal | 12 | 2.6 | 1.5 | 10 |
| deathSignal | 13 | 2.5 | 1.5 | 11 |
| off label use | 10 | 1.9 | 1.1 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.